Global Human Microbiome Market Extected to grow at a CAGR of 8.6% during 2018 -2024

New research report offers a comprehensive analysis of the “Human Microbiome Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2024”. The main objective of this report is to deliver insightful information and clear-cut facts pertaining to the growth trajectories of the market.

Request for Sample Report @ https://www.mrrse.com/sample/2745

Global Human Microbiome Market: Snapshot

With ample unmet needs, the global market for human microbiome exhibits high potential of growth. The market is set to emerge as a lucrative business in the near future, thanks to the increasing emphasis on diagnosis and treatment of various underrated diseases. The worldwide human microbiome market will be US$2.2 bn in 2020. The lack of targeted drugs for specific conditions, such as ulcerative colitis and C.difficile infection across the world makes this market highly opportune for players to set their innovative drug ideas on the path to commercial success. Driven by these factors, the opportunity in this market is slated to rise at a CAGR of 9.80% between 2020 and 2024 and reach US$3.2 bn by the end of 2024.

Microbiome diagnostics and microbiome therapeutics are the two prominent sections of the global human microbiome market. Currently, the market is in the budding phase, with most of the therapies still being in preclinical or clinical (phase I or phase II) stage. The diagnosis technology is also in the development phase and the leading companies have begun to allocate funds for the research and development and the management of clinical studies for their innovative class of therapies. All these factors are likely to propel this market significantly over the next few years. The human microbiome therapeutics market is likely to report a CAGR of 9.20% during the period of 2020 to 2024, whereas the market for human microbiome diagnostics is anticipated to rise at an 8.60% CAGR between 2018 and 2024. 

North America to Report Continued Leadership

North America, Asia Pacific, the Middle East and Africa, Europe, and Latin America are the key regional markets for human microbiome across the world. Thanks to the presence of a state-of-art medical and healthcare industry and early adoption of technology, North America has occupied the top position in the global market. Researchers expect that the rising number of venture-capital funded start-ups and the increasing investments by leading players for research and development of drugs will support the North America market for human microbiome over the forthcoming years, ensuring its dominance. The human microbiome therapeutics market in North America is anticipated to report a rise at a CAGR of 9.10% between 2020 and 2024 while the region’s human microbiome diagnostics market will progress at an 8.80% CAGR from 2018 to 2024.

Browse Full Report with TOC @ https://www.mrrse.com/human-microbiome-market

Europe, which acquired the second position in the global human microbiome market, is projected to maintain its position over the years to come. The U.K. and France have emerged as the key domestic markets for human microbiome in Europe. The high investments by companies in this domain are expected to boost both these domestic markets in the next few years. Apart from this, countries, such as Sweden and the Netherlands, are also anticipated to contribute well to the Europe market for human microbiome market in the near future.

Metagenomic Sequencing to Outpace 16s rRNA in Future

On the basis of technology, the global market for human microbiome is classified into 16s rRNA sequencing and metagenomic sequencing. Both the technology are equally popular platforms for detection in the microbiome-based diagnostics. However, the metagenomic sequencing segment is likely to surpass the 16s rRNA segment over the next few years, albeit by a small margin, as a large number of companies are opting for the diagnosis of a more comprehensive microbiome profile.

At the forefront of the global market for human microbiome are Vedanta Biosciences, Synthetic Biologics Inc., Seres Therapeutics, Second Genome, uBiome Inc., Rebiotix Inc., Osel Inc., MicroBiome Therapeutics LLC., Metabiomics Corp., Enterome Biosciences SA, and AO Biome LLC. Some of the other prominent participants in this market are Metabogen AB, Becton Dickinson & Co., Evelo Biosciences, ARTPred, MaaT Pharma, Blue Turtle Bio Technologies, Axial Therapeutics, Whole Biome, 4D Pharma, Symbiotix Therapies, Phi Therapeutics, Synlogic, and Biospherex LLC.

Enquire about this Report @ https://www.mrrse.com/enquiry/2745

About (MRRSE)

Market Research Reports Search Engine (MRRSE) is an industry-leading database of Market Research Reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords. 

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact Us                            

State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States Telephone: +1-518-730-0559
Email: sales@mrrse.com
Website: https://www.mrrse.com/
Read More Industry News At: https://www.industrynewsanalysis.com/

This release was published on openPR.